Buprenorphine: A Better Option for Opioid Use Disorder Treatment in Pregnancy Compared to Methadone

References

1. 1.↵
   1. Suarez EA,
   2. Huybrechts KF,
   3. Straub L,
   4. et al

   . Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 2022;387:2033–44.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Mascola MA,
   2. Borders AE,
   3. Terplan M

   . Opioid use and opioid use disorder in pregnancy. The American College of Obstetricians and Gynecologists. Accessed May 26, 2023. Available at: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy.
3. 3.↵
   1. Hirai AH,
   2. Ko JY,
   3. Owens PL,
   4. et al

   . Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017 [published correction appears in JAMA 2021; 325:2316]. JAMA 2021;325:146–55.

   OpenUrlCrossRefPubMed
4. 4.↵
   Centers for Disease Control and Prevention. About Opioid Use During Pregnancy. Published November 28, 2022. Accessed May 26, 2023. Available at: https://www.cdc.gov/pregnancy/opioids/basics.html#:∼:text=In%20the%20most%20recent%20estimate,opioid%20pain%20relievers%20during%20pregnancy.
5. 5.↵
   Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130:e81–e94.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mancher M,
   2. Leshner AI

   National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. The effectiveness of medication-based treatment for opioid use disorder. In: Mancher M, Leshner AI, eds. Medications for Opioid Use Disorder Save Lives. Washington (DC): National Academies Press (US); March 30, 2019.
7. 7.↵
   1. Robin A,
   2. Hersh AR,
   3. Caughey AB

   . Buprenorphine Versus methadone in pregnant women with opioid use disorder: a cost-effectiveness analysis [06E]. Obstet Gynecol 2020;135:51S–51S.

   OpenUrl
8. 8.↵
   1. Zedler BK,
   2. Mann AL,
   3. Kim MM,
   4. et al

   . Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016;111:2115–28.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kinsella M,
   2. Halliday LOE,
   3. Shaw M,
   4. et al

   . Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis. Subst Use Misuse 2022;57:1400–16.

   OpenUrlPubMed
10. 10.↵
    1. Wang S,
    2. Meador KJ,
    3. Pawasauskas J,
    4. et al

    . Comparative safety analysis of opioid agonist treatment in pregnant women with opioid use disorder: a population-based study. Drug Saf 2023;46:257–71.

    OpenUrlPubMed
11. 11.↵
    National Institute for Health and Care Research. Black women around the world have worse pregnancy outcomes. Evidence. Accessed October 14, 2023. Available at: https://evidence.nihr.ac.uk/alert/black-women-around-the-world-have-worse-pregnancy-outcomes/.
12. 12.↵
    1. Frellick M

    . Buprenorphine linked with lower risk for neonatal harms than methadone. MDedge Ob Gyn News. November 30, 2022. Accessed September 24, 2023. Available at: https://www.mdedge.com/obgyn/article/259845/opioid-resource-center/buprenorphine-linked-lower-risk-neonatal-harms-methadone.
13. 13.↵
    1. Krans EE

    . Neonatal outcomes after use of buprenorphine during pregnancy. N Engl J Med 2022;387:2085–6.

    OpenUrlPubMed
14. 14.↵
    1. Gregory HM,
    2. Hill VM,
    3. Parker RW

    . Implications of increased access to buprenorphine for medical providers in rural areas: a review of the literature and future directions. Cureus 2021;13:e19870. Published 2021 Nov 24.

    OpenUrlPubMed
15. 15.↵
    1. Abraham R,
    2. Wilkinson E,
    3. Jabbarpour Y,
    4. et al

    . Characteristics of office-based buprenorphine prescribers for Medicare patients. J Am Board Fam Med 2020;33:9–16.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    Substance Abuse and Mental Health Services Administration. Removal of DATA waiver (x-waiver) requirement. April 25, 2023. Accessed May 28, 2023. Available at: https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement.
17. 17.↵
    1. Jain L,
    2. Morrisroe K,
    3. Modesto-Lowe V

    . To use or not to use buprenorphine for illegally manufactured fentanyl. Fam Pract 2023;40:428–30.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Bharat C,
    2. Larney S,
    3. Barbieri S,
    4. et al

    . The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. Addiction 2021;116:3139–52.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Chambers LC,
    2. Hallowell BD,
    3. Zullo AR,
    4. et al

    . Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open 2023;6:e2334540. Published 2023 Sep 5.

    OpenUrlPubMed
20. 20.↵
    Substance Abuse and Mental Health Services Administrative. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Accessed May 28, 2023. Available at: https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf.
21. 21.↵
    HealthPartners. How much will my drugs cost? Accessed May 28, 2023. Available at: https://www.healthpartners.com/hp/pharmacy/drug-cost/index.html.
22. 22.↵
    The Priority Updates from the Research Literature (PURLs) methodology. Available at: https://journals.lww.com/ebp/Documents/PURLs%20Methods%20AC.pdf.